Compare UVV & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UVV | OCS |
|---|---|---|
| Founded | 1886 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | 3 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1994 | N/A |
| Metric | UVV | OCS |
|---|---|---|
| Price | $52.72 | $24.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 152.4K | ★ 353.4K |
| Earning Date | 02-09-2026 | 03-03-2026 |
| Dividend Yield | ★ 6.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.02 | N/A |
| Revenue | ★ $2,922,924,000.00 | N/A |
| Revenue This Year | $0.67 | $466.06 |
| Revenue Next Year | $0.10 | $502.05 |
| P/E Ratio | $17.44 | ★ N/A |
| Revenue Growth | ★ 7.40 | N/A |
| 52 Week Low | $49.96 | $14.00 |
| 52 Week High | $67.33 | $30.68 |
| Indicator | UVV | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 49.58 | 37.93 |
| Support Level | $51.79 | $19.00 |
| Resistance Level | $53.95 | $29.19 |
| Average True Range (ATR) | 0.85 | 1.21 |
| MACD | 0.08 | -0.25 |
| Stochastic Oscillator | 65.08 | 11.59 |
Universal Corp is an international leaf tobacco supplier. The company procures leaf tobacco from farmers, processes it, and sells it to companies that manufacture consumer tobacco products. Universal does not manufacture or sell any consumer products itself. The company's segments include Tobacco Operations and Ingredients Operations. It generates maximum revenue from the Tobacco Operations segment. Geographically, it derives a majority of revenue from the United States. The company operates in the USA, Belgium, China, Egypt, Philippines, Germany, and Other Countries with majority of revenue from USA.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.